Raif Coşkun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raif Coşkun has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Aslı Gelincik
Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine Istanbul University Istanbul Türkiye
4 shared publications - Semra Demir
Division of Immunology and Allergy Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Türkiye
4 shared publications - Müge Olgaç
Division of Allergy and Clinical Immunology Department of Internal Medicine Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
3 shared publications - Nida Öztop
Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital
3 shared publications - Osman Ozan Yeğit
Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye
3 shared publications - Pelin Karadağ
Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
3 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Acta Paediatrica
Factors Associated With Omalizumab Response in Chronic Spontaneous Urticaria: Are There Age‐Related Differences?
Aim: This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods: The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated. Results: In adults, higher baseline Systemic Inflammation Response Index (SIRI) (OR = 0.207, p < 0.001), monocyte count (OR = 0.276, p = 0.002), neutrophil‐to‐lymphocyte ratio (NLR) (OR = 0.455, p = 0.012), and Systemic Immune‐Inflammation Index (SII) (OR = 0.487, p = 0.022) were associated with lower odds of treatment response. In paediatric patients, higher baseline SII was significantly associated with lower odds of response (OR = 0.349, p = 0.040). Interaction analyses showed nominally significant age interactions for baseline SIRI (B = −0.169, p = 0.027) and monocyte count (B = −0.193, p = 0.025). During follow‐up, SIRI was lower in responders from baseline through 12 months in adults, and at 3 and 6 months in children. SII was lower in responders at baseline in adults, and at baseline, 3, and 6 months in children (all p < 0.05). Conclusion: Our findings suggest potential differences in the associations between inflammatory markers and omalizumab response across age groups, though further studies are needed to clarify age‐related differences.
- 8 September 2026
- Published by Wiley in Acta Paediatrica
Open AccessFactors Associated With Omalizumab Response in Chronic Spontaneous Urticaria: Are There Age‐Related Differences?
Aim: This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods: The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated. Results: In adults, higher baseline Systemic Inflammation Response Index (SIRI) (OR = 0.207, p < 0.001), monocyte count (OR = 0.276, p = 0.002), neutrophil‐to‐lymphocyte ratio (NLR) (OR = 0.455, p = 0.012), and Systemic Immune‐Inflammation Index (SII) (OR = 0.487, p = 0.022) were associated with lower odds of treatment response. In paediatric patients, higher baseline SII was significantly associated with lower odds of response (OR = 0.349, p = 0.040). Interaction analyses showed nominally significant age interactions for baseline SIRI (B = −0.169, p = 0.027) and monocyte count (B = −0.193, p = 0.025). During follow‐up, SIRI was lower in responders from baseline through 12 months in adults, and at 3 and 6 months in children. SII was lower in responders at baseline in adults, and at baseline, 3, and 6 months in children (all p < 0.05). Conclusion: Our findings suggest potential differences in the associations between inflammatory markers and omalizumab response across age groups, though further studies are needed to clarify age‐related differences.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- Open Access
- 26 August 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (8) , 100810
Comparison of recent anaphylaxis diagnostic criteria in real life: Can more patients be diagnosed as having anaphylaxis?
- 26 August 2023
- Published by Elsevier in World Allergy Organization Journal
- Vol. 16 (8) , 100810
Open AccessComparison of recent anaphylaxis diagnostic criteria in real life: Can more patients be diagnosed as having anaphylaxis?
- Open Access
- 1 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (2) , 189-197
Impacto da pandemia de COVID‐19 no curso da urticária crônica espontânea refratária em tratamento com omalizumabe
- 1 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (2) , 189-197
Open AccessImpacto da pandemia de COVID‐19 no curso da urticária crônica espontânea refratária em tratamento com omalizumabe
- Open Access
- 14 December 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (2) , 189-197
Impact of COVID-19 pandemic on the course of refractory chronic spontaneous urticaria under omalizumab treatment
- 14 December 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (2) , 189-197
Open AccessImpact of COVID-19 pandemic on the course of refractory chronic spontaneous urticaria under omalizumab treatment